Ladrx Revenue Growth Rates (LADX), Current and Historic Growth - CSIMarket
CSIMarket
 


Ladrx Corporation  (LADX)
 

LADX's Revenue Growth by Quarter and Year

Ladrx's Revenue results by quarter and year




LADX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.00
FY 0.00





LADX Revenue first quarter 2025 Y/Y Growth Comment
Ladrx Corporation in the first quarter 2025 recorded of $ 0.00 millions.

According to the results reported in the first quarter 2025, Ladrx Corporation achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Ladrx Corporation' s Revenue no change of 0% ranks overall at the positon no. in the first quarter 2025.




LADX Revenue ( Y/Y Growth %) 2025
2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Ladrx's first quarter 2025 Revenue $ 0.00 millions LADX's Income Statement
Ladrx's first quarter 2024 Revenue $ 0.00 millions Quarterly LADX's Income Statement


LADX Revenue (Quarter on Quarter Growth %)

2025
2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -




Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Ladrx's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LADX's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LADX's I. Quarter Q/Q Revenue Comment


Ladrx's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)
12 Months Ending
(Dec 31 2024)
12 Months Ending
(Sep 30 2024)
12 Months Ending
(Jun 30 2024)
12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Mar 31 2025 period, Ladrx's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ladrx Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Mar 31 2025 period, Ladrx's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Ladrx Corporation achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LADX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Carlisle Companies Incorporated-0.06%$ -0.064 millions
Henry Schein Inc -0.13%$ -0.126 millions
Tactile Systems Technology Inc -0.14%$ -0.137 millions
Alpha Pro Tech Ltd -0.19%$ -0.186 millions
Premier Air Charter Holdings Inc -0.20%$ -0.204 millions
Gilead Sciences Inc -0.28%$ -0.284 millions
Adm Tronics Unlimited Inc -0.32%$ -0.315 millions
Jazz Pharmaceuticals Plc-0.46%$ -0.459 millions
Milestone Scientific Inc -0.73%$ -0.730 millions
Logicmark Inc-0.74%$ -0.738 millions
Yunhong Green Cti Ltd -0.74%$ -0.745 millions
Amphastar Pharmaceuticals Inc -0.76%$ -0.761 millions
Enhabit Inc -0.95%$ -0.953 millions
Elanco Animal Health Incorporated-1.00%$ -0.996 millions
3m Company-1.03%$ -1.031 millions
Envista Holdings Corporation-1.17%$ -1.171 millions
Globus Medical Inc -1.41%$ -1.409 millions
Proqr Therapeutics N v -1.53%$ -1.528 millions
Merck and Co Inc -1.56%$ -1.559 millions
Icad Inc-1.61%$ -1.615 millions
Fortrea Holdings Inc -1.63%$ -1.631 millions
Align Technology inc -1.78%$ -1.776 millions
Adapthealth Corp -1.84%$ -1.844 millions
Sunlink Health Systems Inc -2.05%$ -2.050 millions
Tonix Pharmaceuticals Holding Corp -2.14%$ -2.135 millions
Alpha Teknova Inc -2.19%$ -2.194 millions
Quidelortho Corp-2.56%$ -2.560 millions
Teladoc Health Inc -2.59%$ -2.594 millions
Tenet Healthcare Corp-2.70%$ -2.701 millions
Charles River Laboratories International inc -2.71%$ -2.708 millions


About Ladrx Revenue Growth Rates (LADX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Ladrx Corp (CIK 799698).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001641172-25-010063
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Ladrx Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.